Tislelizumab Boosts Tumour Response Before Surgery In Rectal Cancer

New Delhi, August 20, 2026 | Adding the immunotherapy drug tislelizumab to standard pre-surgery radiotherapy and chemotherapy nearly doubled rates of major tumour regression in patients with locally advanced rectal cancer, according to early results from a phase II trial in China. The Neo-STAR study also showed a trend toward...